(Q38061474)

28 August 2017

1 reference

title

Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions (English)

1 reference

28 August 2017

3

Maarten J Postma

1 reference

28 August 2017

Raymond A Farkouh

1

1 reference

28 August 2017

Rogier M Klok

series ordinal

2

1 reference

28 August 2017

Craig S Roberts

series ordinal

4

1 reference

28 August 2017

David R Strutton

series ordinal

5

1 reference

28 August 2017

publication date

1 October 2012

1 reference

Expert Review of Vaccines

28 August 2017

published in

1 reference

28 August 2017

volume

11

1 reference

28 August 2017

issue

10

1 reference

28 August 2017

page(s)

1235-1247

1 reference

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

28 August 2017

cites work

1 reference

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

21 January 2018

1 reference

Cost-effectiveness analysis of pneumococcal vaccination in Spain

21 January 2018

1 reference

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model

21 January 2018

1 reference

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries

21 January 2018

1 reference

[Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].

21 January 2018

1 reference

Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil.

21 January 2018

1 reference

Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise

21 January 2018

1 reference

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines

21 January 2018

1 reference

Economic evaluation of pneumococcal conjugate vaccination in The Gambia

21 January 2018

1 reference

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines

21 January 2018

1 reference

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

21 January 2018

1 reference

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

21 January 2018

1 reference

Impact of the pneumococcal conjugate vaccine on otitis media

21 January 2018

1 reference

Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy

21 January 2018

1 reference

Multinational study of pneumococcal serotypes causing acute otitis media in children.

21 January 2018

1 reference

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

21 January 2018

1 reference

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

21 January 2018

1 reference

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review

21 January 2018

1 reference

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

21 January 2018

1 reference

Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.

21 January 2018

1 reference

Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands

21 January 2018

1 reference

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

21 January 2018

1 reference

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.

21 January 2018

1 reference

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

21 January 2018

1 reference

Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study

21 January 2018

1 reference

Nasopharyngeal pneumococcal carriage of children attending day care centers in Korea: comparison between children immunized with 7-valent pneumococcal conjugate vaccine and non-immunized.

21 January 2018

1 reference

Continued impact of pneumococcal conjugate vaccine on carriage in young children.

21 January 2018

1 reference

Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age.

21 January 2018

1 reference

Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

21 January 2018

1 reference

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

21 January 2018

1 reference

Clonal replacement among 19A Streptococcus pneumoniae in Massachusetts, prior to 13 valent conjugate vaccination.

21 January 2018

1 reference

Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains

21 January 2018

1 reference

Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

21 January 2018

1 reference

Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.12.99

1 reference

28 August 2017

1 reference